SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-14
DOI
10.1038/s41598-021-80999-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment
- (2020) Elsa Quintana et al. CANCER RESEARCH
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Macrophage Polarization in the Development and Progression of Ovarian Cancers: An Overview
- (2019) Huiyan Cheng et al. Frontiers in Oncology
- Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
- (2019) Cristina Segovia et al. NATURE MEDICINE
- Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers
- (2019) Huai-Xiang Hao et al. MOLECULAR CANCER THERAPEUTICS
- Targeting SHP2 as a promising strategy for cancer immunotherapy
- (2019) Qianqian Liu et al. PHARMACOLOGICAL RESEARCH
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment
- (2018) P. Xiao et al. ONCOGENE
- Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
- (2018) David Wang et al. Cell Reports
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors
- (2018) Viviana Cremasco et al. Cancer Immunology Research
- SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
- (2018) Mingxia Zhao et al. Acta Pharmaceutica Sinica B
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
- (2018) Huayang Liu et al. NATURE MEDICINE
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Identification of essential genes for cancer immunotherapy
- (2017) Shashank J. Patel et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade
- (2017) Maria Ouzounova et al. Nature Communications
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer
- (2016) Daniela Achkova et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
- (2016) Sylvia Herter et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained
- (2016) Michele Zanoni et al. Scientific Reports
- Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
- (2015) Meagan S. Barbee et al. ANNALS OF PHARMACOTHERAPY
- CXCR3 ligands in disease and therapy
- (2015) Katrien Van Raemdonck et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Functions of Shp2 in cancer
- (2015) Jie Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Anti-PD-L1 antibody active in metastatic bladder cancer
- (2015) Vicki Brower LANCET ONCOLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
- (2014) Scott Gettinger et al. CANCER JOURNAL
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Inhibition of IFN- -Induced STAT1 Tyrosine Phosphorylation by Human CMV Is Mediated by SHP2
- (2014) M. Baron et al. JOURNAL OF IMMUNOLOGY
- The anticancer effects of HDAC inhibitors require the immune system
- (2014) Alison C West et al. OncoImmunology
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
- (2013) P. Leone et al. JNCI-Journal of the National Cancer Institute
- Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis
- (2013) Tao Zhang et al. Scientific Reports
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- CXCR3 ligands: redundant, collaborative and antagonistic functions
- (2011) Joanna R Groom et al. IMMUNOLOGY AND CELL BIOLOGY
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
- (2009) Xiaoyu Hu et al. IMMUNITY
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Impaired interferon signaling is a common immune defect in human cancer
- (2009) R. J. Critchley-Thorne et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now